Factor Xa inhibitors are a type of anticoagulant, or blood thinner. They’re a short- and long-term therapy for venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary ...

If you live with atrial fibrillation (sometimes called AF or AFib), a type of irregular heartbeat, you probably take a blood thinner to reduce your risk of stroke and blood clots. Research shows that ...

Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant ...

Safe and effective stroke prevention in atrial fibrillation (AF) is crucial as the number of patients with this condition continues to increase. Several novel oral anticoagulants are being developed ...

Obesity is associated with an increased risk of VTE, and it has been postulated that standard prophylactic LMWH doses may be insufficient to prevent VTE or achieve suggested anti-factor Xa target ...

We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexanet, followed by a 2-hour infusion. The ...

ORLANDO, FL—A new interim analysis of the ongoing ANNEXA-4 study evaluating andexanet alfa (AndexXa; Portola Pharmaceuticals) affirms that the drug rapidly reverses the anticoagulant effects of the ...

New research sheds light on the mechanism by which Rivaroxaban suppresses factor Xa and successfully attenuates atherosclerosis. New research by a team led by researchers from the Department of ...

Despite considerable reductions in cardiovascular events in patients with an acute coronary syndrome (ACS) receiving dual antiplatelet therapy (DAPT), substantial residual risk persists. This unmet ...

Please provide your email address to receive an email when new articles are posted on . In recent years, medicine has witnessed the arrival of the direct oral anticoagulants, which include the direct ...